Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab, Business News – AsiaOne
BENGALURU, India, Feb. 9, 2024 /PRNewswire/ — Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG (‘Sandoz’) which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar
Read More
0
